WO2000009108A3 - Compositions and uses for vision and memory disorders - Google Patents

Compositions and uses for vision and memory disorders Download PDF

Info

Publication number
WO2000009108A3
WO2000009108A3 PCT/US1999/018241 US9918241W WO0009108A3 WO 2000009108 A3 WO2000009108 A3 WO 2000009108A3 US 9918241 W US9918241 W US 9918241W WO 0009108 A3 WO0009108 A3 WO 0009108A3
Authority
WO
WIPO (PCT)
Prior art keywords
vision
compositions
memory disorders
treating
memory
Prior art date
Application number
PCT/US1999/018241
Other languages
French (fr)
Other versions
WO2000009108A2 (en
Inventor
Douglas T Ross
Hansjorg Sauer
Gregory S Hamilton
Joseph P Steiner
Original Assignee
Guilford Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guilford Pharm Inc filed Critical Guilford Pharm Inc
Priority to AU55556/99A priority Critical patent/AU5555699A/en
Priority to EP99942108A priority patent/EP1105112A2/en
Priority to JP2000564611A priority patent/JP4503180B2/en
Priority to CA002335815A priority patent/CA2335815A1/en
Publication of WO2000009108A2 publication Critical patent/WO2000009108A2/en
Publication of WO2000009108A3 publication Critical patent/WO2000009108A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

This invention relates to novel compositions and uses of non-immunosuppressive FKBP neuroimmunophilin ligands for treating a vision disorder, improving vision, treating memory impairment or enhancing memory performance in an animal.
PCT/US1999/018241 1998-08-14 1999-08-12 Compositions and uses for vision and memory disorders WO2000009108A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU55556/99A AU5555699A (en) 1998-08-14 1999-08-12 Compositions and uses for vision and memory disorders
EP99942108A EP1105112A2 (en) 1998-08-14 1999-08-12 Compositions and uses for vision and memory disorders
JP2000564611A JP4503180B2 (en) 1998-08-14 1999-08-12 Compositions and uses for vision and memory impairment
CA002335815A CA2335815A1 (en) 1998-08-14 1999-08-12 Compositions and uses for vision and memory disorders

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13442298A 1998-08-14 1998-08-14
US09/134,422 1998-08-14

Publications (2)

Publication Number Publication Date
WO2000009108A2 WO2000009108A2 (en) 2000-02-24
WO2000009108A3 true WO2000009108A3 (en) 2000-05-18

Family

ID=22463332

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/018241 WO2000009108A2 (en) 1998-08-14 1999-08-12 Compositions and uses for vision and memory disorders

Country Status (5)

Country Link
EP (1) EP1105112A2 (en)
JP (1) JP4503180B2 (en)
AU (1) AU5555699A (en)
CA (1) CA2335815A1 (en)
WO (1) WO2000009108A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6218424B1 (en) * 1996-09-25 2001-04-17 Gpi Nil Holdings, Inc. Heterocyclic ketone and thioester compounds and uses
AU6497200A (en) * 1999-07-30 2001-02-19 Vertex Pharmaceuticals Incorporated Acyclic and cyclic amine derivatives
ES2269206T3 (en) * 1999-11-12 2007-04-01 Alcon, Inc. NEUROPHILINE LIGANDS TO TREAT EYE DISORDERS.
CN1240691C (en) 2001-12-06 2006-02-08 中国人民解放军军事医学科学院毒物药物研究所 Substituted penta azacylo compounds and their use for preventing and treating nervous retrogression disease

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992000278A1 (en) * 1990-07-02 1992-01-09 Vertex Pharmaceuticals Incorporated Novel immunosuppressive compounds
WO1992019593A1 (en) * 1991-05-09 1992-11-12 Vertex Pharmaceuticals Incorporated Novel immunosuppressive compounds
WO1996040140A1 (en) * 1995-06-07 1996-12-19 Guilford Pharmaceuticals Inc. Inhibitors of rotamase enzyme activity
WO1996040633A1 (en) * 1995-06-07 1996-12-19 Guilford Pharmaceuticals Inc. Small molecule inhibitors of rotamase enzyme activity
WO1996041609A2 (en) * 1995-06-08 1996-12-27 Vertex Pharmaceuticals Incorporated Methods and compositions for stimulating neurite growth
WO1997016190A1 (en) * 1995-10-31 1997-05-09 Guilford Pharmaceuticals Inc. Rotamase enzyme activity inhibitors
WO1997031020A1 (en) * 1996-02-22 1997-08-28 The General Hospital Corporation METHODS AND COMPOSITIONS FOR ENHANCING CELLULAR RESPONSE TO TGF-β LIGANDS
WO1998013343A1 (en) * 1996-09-25 1998-04-02 Guilford Pharmaceuticals Inc. Heterocyclic thioesters and ketones
WO1998013355A1 (en) * 1996-09-25 1998-04-02 Guilford Pharmaceuticals Inc. Heterocyclic esters and amides
WO1998037885A1 (en) * 1997-02-28 1998-09-03 Guilford Pharmaceuticals Inc. N-oxides of heterocyclic esters, amides, thioesters, and ketones
WO1998048784A2 (en) * 1997-04-28 1998-11-05 The University Of British Columbia Method and composition for modulating amyloidosis
EP0947506A1 (en) * 1998-03-24 1999-10-06 Pfizer Products Inc. 2-Aza-bicyclo[2.2.1]heptane derivatives and their use as rotamase inhibitors

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992000278A1 (en) * 1990-07-02 1992-01-09 Vertex Pharmaceuticals Incorporated Novel immunosuppressive compounds
WO1992019593A1 (en) * 1991-05-09 1992-11-12 Vertex Pharmaceuticals Incorporated Novel immunosuppressive compounds
WO1996040140A1 (en) * 1995-06-07 1996-12-19 Guilford Pharmaceuticals Inc. Inhibitors of rotamase enzyme activity
WO1996040633A1 (en) * 1995-06-07 1996-12-19 Guilford Pharmaceuticals Inc. Small molecule inhibitors of rotamase enzyme activity
WO1996041609A2 (en) * 1995-06-08 1996-12-27 Vertex Pharmaceuticals Incorporated Methods and compositions for stimulating neurite growth
WO1997016190A1 (en) * 1995-10-31 1997-05-09 Guilford Pharmaceuticals Inc. Rotamase enzyme activity inhibitors
WO1997031020A1 (en) * 1996-02-22 1997-08-28 The General Hospital Corporation METHODS AND COMPOSITIONS FOR ENHANCING CELLULAR RESPONSE TO TGF-β LIGANDS
WO1998013343A1 (en) * 1996-09-25 1998-04-02 Guilford Pharmaceuticals Inc. Heterocyclic thioesters and ketones
WO1998013355A1 (en) * 1996-09-25 1998-04-02 Guilford Pharmaceuticals Inc. Heterocyclic esters and amides
WO1998037885A1 (en) * 1997-02-28 1998-09-03 Guilford Pharmaceuticals Inc. N-oxides of heterocyclic esters, amides, thioesters, and ketones
WO1998048784A2 (en) * 1997-04-28 1998-11-05 The University Of British Columbia Method and composition for modulating amyloidosis
EP0947506A1 (en) * 1998-03-24 1999-10-06 Pfizer Products Inc. 2-Aza-bicyclo[2.2.1]heptane derivatives and their use as rotamase inhibitors

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
H. GUO ET AL.: "The novel small molecule immunophilin ligand GPI 1046 stimulates cholinergic reinnervation of dearrerented hippocampal regions after fimbria-fornix transection", SOCIETY FOR NEUROSCIENCE ABSTRACTS, vol. 23, no. 1-2, 1997, pages 1729, XP000878535 *
J.P. STEINER ET AL.: "Neurotrophic immunophilin ligands stimulate structural and functional recovery in neurodegenerative animal models", PROC. NATL. ACAD. SCI., vol. 94, no. 5, 1997, pages 2019 - 2024, XP000876505 *
PESSAH, I. N. (1): "Role for the major T-cell immunophilin FKBP12 in mediating neurotoxicity of non-coplanar PCBs.", NEUROTOXICOLOGY AND TERATOLOGY, (MAY-JUNE, 1998) VOL. 20, NO. 3, PP. 350. MEETING INFO.: TWENTY-SECOND ANNUAL MEETING OF THE NEUROBEHAVIORAL TERATOLOGY SOCIETY SAN DIEGO, CALIFORNIA, USA JUNE 20-24, 1998 NEUROBEHAVIORAL TERATOLOGY SOCIETY., XP000878599 *
ROSS, D. T. ET AL: "The FKBP neuroimmunophilin ligand GPI - 1046 enhances retinal ganglion cell survival and arrests axonal dying back following optic nerve transection.", SOCIETY FOR NEUROSCIENCE ABSTRACTS, (1998) VOL. 24, NO. 1-2, PP. 814. MEETING INFO.: 28TH ANNUAL MEETING OF THE SOCIETY FOR NEUROSCIENCE, PART 1 LOS ANGELES, CALIFORNIA, USA NOVEMBER 7-12, 1998 SOCIETY FOR NEUROSCIENCE., XP000878539 *
SAUER, H. ET AL: "Effects of chronic GPI - 1046 administration on spatial learning and memory in aged rodents.", SOCIETY FOR NEUROSCIENCE ABSTRACTS, (1998) VOL. 24, NO. 1-2, PP. 686. MEETING INFO.: 28TH ANNUAL MEETING OF THE SOCIETY FOR NEUROSCIENCE, PART 1 LOS ANGELES, CALIFORNIA, USA NOVEMBER 7-12, 1998 SOCIETY FOR NEUROSCIENCE., XP000878538 *

Also Published As

Publication number Publication date
CA2335815A1 (en) 2000-02-24
AU5555699A (en) 2000-03-06
EP1105112A2 (en) 2001-06-13
JP4503180B2 (en) 2010-07-14
WO2000009108A2 (en) 2000-02-24
JP2002522484A (en) 2002-07-23

Similar Documents

Publication Publication Date Title
ES2159318T3 (en) INHIBITORS OF PROTEIN QUINASA C.
WO2001079460A3 (en) Polypeptides having haloperoxidase activity
CA2292910A1 (en) Hair growth compositions and uses
AU6064696A (en) Water and oil repellent composition, treating method therewith and copolymer
WO2001079458A3 (en) Polypeptides having haloperoxidase activity
WO2002072022A3 (en) Substituted tetracycline compounds as antifungal agents
WO2002057293A3 (en) Modified zinc finger binding proteins
WO2003015694A3 (en) Agents for enhancing the immune response
CA2416976A1 (en) Treatment of estrogen receptor positive carcinoma with a rapamycin and an antiestrogen
ZA975936B (en) Fuel oil compositions.
PT1144474E (en) MASSES OF TOOLING AQUOSAS REACTIVAS
BR9912040B1 (en) Depth valve, and well finish.
AU2002366641A1 (en) Methods for inhibiting ocular processes
AU4991299A (en) Compositions and methods for fumonisin detoxification
HK1042720A1 (en) Copolymer (composition) for modifying asphalt and asphalt compositions.
ZA200106160B (en) Compositions and methods for treating cataracts.
CA2319541A1 (en) Cardable blends of dual glass fibers
ZA967463B (en) Compositions and methods for controlling harmful fungi.
AU7955398A (en) Hair conditioning composition comprising poly alpha-olefin oil
MA24452A1 (en) LOW TINT PHOTOBLANCHIMENT AGENTS.
WO2000052479A3 (en) Diagnostics and therapeutics for drusen associated ocular disorders
WO2000009112A3 (en) Heterocyclic esters or amides for vision and memory disorders
WO2000009108A3 (en) Compositions and uses for vision and memory disorders
WO2001015677A3 (en) Use of 5-ht1b/1d agonists to treat otic pain
WO2000009479A3 (en) Heterocyclic thioesters or ketones for vision and memory disorders

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 2335815

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1999942108

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 55556/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/000196

Country of ref document: MX

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1999942108

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1999942108

Country of ref document: EP